APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 SERIAL NO. U.S ARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTY DOCKET NO. 09/632,056 **STI-201CN2** LIST OF PUBLICATIONS CITED BY APPLICANT (Use several sheets in necessary) Clifford A. Lingwood et al 1633 August 3, 2000 **U.S. PATENT DOCUMENTS** 

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
las	A1	5,801,145	09/98	Gariepy	514	12	
1							

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	Country	CLASS	SUBCLASS	TRANSLATION	
						YES_	NO
			<del></del>				

OTHERS (including Author Title Date Pertinent Pages Etc.)

		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)						
- 1	A2	Farkas-Himsley, et al: "Bacterial Proteinaceous Products (Bacteriocins) as Cytotoxic Agents of						
Set.		Neoplasia", Cancer Research, vol. 36, pp. 3562-3567 (Oct. 1976).						
()'	А3	Hill, et al: "Further studies of the Action of a Partially Purified Bacteriocin against a Murine						
$J_{I}$		Fibrosarcoma", Cancer Research, vol. 51, pp. 1359-1365 (March 1, 1991)						
	A4	Karmali: "Infection by Verocytotoxin-Producing Escherichia coli", Clinical Microbiology Reviews,						
-		vol. 2, no. 1, pp. 15-38 (Jan. 1989)						
	A5	Riley, et al: "Hemorrhagic Colitis Associated with a Rare Escherichia Coli Serotype", The New						
- 1		England Journal of Medicine, vol. 308, no. 12, pp. 681-685 (March 24, 1983)						
	A6	Lingwood: "Verotoxin and Their Glycolipid Receptors", Advances in Lipid Research, vol. 25, pp.						
İ		189-211 (1993)						
	A7	van de Kar, et al: "Tumor Necrosis Factor and Interleukin-1 Induce Expression of the						
		Verocytotoxin Receptor Globotriaosylceramide on Human Endothelial Cells: Implications						
	A8	Obrig, et al. "Endothelial Heterogeneity in Shiga Toxin Receptors and Responses", The Journal						
1	'	of Biological Chemistry, vol. 268, no. 21, pp. 15484-15488 (July 25, 1993)						
	A9	Lingwood: "Verotoxin-Binding in Human Renal Sections", Nephron, vol. 66, pp. 21-28 (1994)						
	A10	Cohen, et al: "Expression of Glycolipid Receptors to Shiga-like Toxin on Human B Lymphocytes:						
İ		a Mechanism for the failure of long-lived antibody response to dysenteric disease", International						
		Immunology, vol. 2, no. 1, pp. 1-8 (1990)						
	A11	Gregory, et al: "Identification of a Subset of Normal B Cells with a Burkitt's Lymphoma (BL)-Like						
		Phenotype", <i>The Journal of Immunology</i> , vol. 139, no. 1, pp. 313-318 (July 1, 1987)						
	A12	Maloney, et al: "CD19 has a Potential CD77 (Globotriaosyl Ceramide)-binding Site with						
		Sequence Similiarity to Verotoxin B-subunits: Implications of Molecular Mimicry for B Cell						
- 1		Adhesion and Enterohemorrhagic Escherichia Coli Pathogenesis", J. Exp. Med., vol. 180, pp.						
		191-201 (July 1994)						
Maloney, et al: "Interaction of Verotoxins with Glycosphingolipids", <i>Trends in Glycoscie</i>								
	Glycotechnology, vol. 5, no. 21, pp. 23-31 (January 1993)							
	A14	Li, et al: "Accumulation of Globotriaosylceramide in a case of Leiomyosarcoma", <i>Biochemistry</i> J., vol. 240, pp. 925-927 (1986)						
	A15	Mannori, et al: "Role of Glycolipids in the Metastatic Process: Characteristics of Neutral						
		Glycolipids in Clones with Different Metastatic Potentials Isolated from a Murine Fibrosarcoma						
1	A16	Ohyama, et al: "Changes in Glycolipid Expression in Human Testicular Tumor", Intl. J. Cancer,						
4		vol. 45, pp. 1040-1044 (1990)						
Examine	r o	Date Considered/						
//.	, K	$\frac{1}{2}$						

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APPLICANT	FACSIMILE	OF	FORM	PTO-1449
REV 7-80				



ATTY DOCKET NO.

APPLICANT

STI-201CN2

09/632,056

(Use several sheets if necessary)

DEC 2 0 2000 C

Clifford A. Lingwood et al.

August 3, 2000

1633

OF 58 JUL

THERS (Micluding Author, Title, Date, Pertinent Pages, Etc.) Naiki, et al: "Human Erythrocyte P and Pk Blood Group Antigens: Identification as Glycosphingolipids", Biochemical and Biophysical Research Communications, vol. 60, no. 3, pp. 1105-1111 (1974) В2 Pallesen, et al: "Distribution of the Burkitt's Lymphoma-associated Antigen (BLA) in Normal Human Tissue and Malignant Lymphoma as Defined by Immunohistological Staining with Monoclonal Antibody 38.13", J. Cancer Res. Clin. Oncol., vol. 113, pp. 67-86 (1987) Kasai, et al: "Tissue Distribution of the Pk Antigen as Determined by a Monoclonal Antibody", Journal of Immunogenetics, vol. 12, pp. 213-220 (1985) Pudymaitis, et al: "Susceptibility to Verotoxin as a Function of the Cell Cycle", Journal of Cellular Physiology, vol. 150, pp. 632-639 (1992) **B**5 Lingwood, et al: "Glycolipid Modification of α2 Interferon Binding", Biochem, J., vol. 283, pp. 25-26 (1992) В6 Sandvig, et al: "Retrograde Transport of Endocytosed Shiga Toxin to the Endoplasmic Reticulum", Nature, vol. 358, pp. 510-512 (August 6, 1992) В7 Mangeney, et al: "Apoptosis induced in Burkitt's lymphoma cells via Gb<sub>3</sub>/CD77, a glycolipid antigen", Cancer Res., vol. 53, pp. 5314-5319 (1993) Costello, et al. "Human cerebral endothelium; Isolation and characterization of cell derived from microvessels of non-neoplastic and malignant glial tissue" J. Neuro Oncol., vol. 8, pp. 231-243 (1990)В9 Pintus, et al. "Endothelial cell growth supplement: a cell cloning factor that promotes the growth of mono-clonal antibody producing hydridoma cells", J. Immunological Methods, vol. 61, pp. 195-200 (1983) Rutka, et al. "Characterization of normal human brain cultures: Evidence for the outgrowth of leptomeningeal cells", Laboratory Investigation, vol. 55, pp. 71-85 (1986) B11 Sandvig et al. "Toxin Induced Cell Lysis: Protection by 3-Methyladenine and Cycloheximide" EXP CELL, vol. 200, pp. 253-262 (1992). Head, et al.: "Purification and characterization of verocytotoxin 2", FEMS Microbiology Letters, 51, pp. 211-216 (1988) Ramotar, et al. "Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron", Biochem. J., vol. 272, pp. 805-811 (1990) Bugask Date Considered Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through

Iditial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.